Preliminary Evaluation of Potential Properties of Three Probiotics and Their Combination with Prebiotics on GLP-1 Secretion and Type 2 Diabetes Alleviation
Preliminary Evaluation of Potential Properties of Three Probiotics and Their Combination with Prebiotics on GLP-1 Secretion and Type 2 Diabetes Alleviation
复制标题
三种益生菌及其与益生元组合对 GLP-1 分泌和缓解 2 型糖尿病的潜在特性的初步评价
作者：
Ran Xiao;Ran Wang;Shusen Li;Xiaohong Kang;Yimei Ren;E. Sun;Chenyuan Wang;Jingjing He;Jing Zhan
2型糖尿病（T2 D）是一种全球关注的疾病，其特征是高血糖和胰岛素抵抗。许多研究发现，胰高血糖素样肽-1（GLP-1）是一种肠促胰岛素激素，可以缓解高血糖和T2 D。近年来，益生菌及其与益生元的组合被发现在血糖调节和T2 D缓解方面显示出巨大的潜力。鉴于GLP-1在T2 D中的重要作用，筛选具有促进GLP-1分泌能力的益生菌对于提供T2 D治疗的新应用有很大帮助。在本研究中，我们评估了三种益生菌，即副干酪乳杆菌LC-37（LC-37）、动物双歧杆菌MN-Gup（MN-Gup）和长双歧杆菌BBMN 68（BBMN 68），以及它们与益生元的组合对NCI-H716细胞促进GLP-1分泌的作用。结果显示，LC-37和MN-Gup能刺激NCI-H716细胞分泌更多的GLP-1，BBMN 68对GLP-1的分泌无明显影响。进一步的评价表明，LC-37与异麦芽糖低聚糖（IMO）和MN-Gup与半乳糖低聚糖（GOS）的两种组合在体外促进GLP-1分泌方面具有最佳性能。随后，使用高脂饮食（HFD）和链脲佐菌素（STZ）处理的大鼠在体内研究两种组合对促进GLP-1分泌和缓解T2 D的作用。结果表明，这两种组合可以显着降低空腹血糖水平，改善胰岛素抵抗，并调节血脂谱在HFD/STZ治疗的大鼠。这些结果将有助于了解LC-37和MN-Gup促进GLP-1分泌的潜力，并为其在发酵乳或其他食品中的应用提供理论依据。
Type 2 diabetes (T2D) is a disease of global concern characterized by hyperglycemia and insulin resistance. Many studies found that glucagonlike peptide-1 (GLP-1) is an incretin hormone that can alleviate hyperglycemia and T2D. Recently, probiotics and their combination with prebiotics have been found to show great potentials of blood glucose regulation and T2D alleviation. Given the important role of GLP-1 in T2D, screening probiotics with the capacity of promoting GLP-1 secretion is of great help for providing a novel application of T2D treatment. In the current study, we evaluated the effects of three probiotics, namely, Lactobacillus paracasei LC-37 (LC-37), Bifidobacterium animals MN-Gup (MN-Gup), and Bifidobacterium longum BBMN68 (BBMN68), and their combination with prebiotics on promoting GLP-1 secretion using NCI-H716 cells. The results showed that LC-37 and MN-Gup could stimulate more GLP-1 secretion in NCI-H716 cells, but BBMN68 had no significant effect. Further evaluation suggested that the two combinations of LC-37 with isomaltooligosaccharide (IMO) and MN-Gup with galactooligosaccharide (GOS) had the best performance on promoting GLP-1 secretion in vitro. Subsequently, the effects of the two combinations on promoting GLP-1 secretion and alleviating T2D were investigated in vivo using high fat diet (HFD) and streptozotocin (STZ) treated rats. The results showed that the two combinations could significantly reduce fasting blood glucose levels, improve insulin resistance, and modulate serum lipid profiles in HFD/STZ-treated rats. These results will help understand the potential of promoting GLP-1 secretion of LC-37 and MN-Gup and provide theoretical basis for their applications in fermented milk or other foods.